ACLASTA® (zoledronic acid)

See more

AFINITOR® (everolimus)

See more

AIMOVIG® (erenumab)

See more

ATECTURA® BREEZHALER® (indacaterol (as acetate)/mometasone furoate)

See more

ATRIANCE® (nelarabine)

See more

AZARGA® (brinzolamide / timolol (as timolol maleate))

See more

AZOPT® (brinzolamide)

See more

BEOVU® (brolucizumab)

See more

CATAFLAM® (diclofenac potassium)

See more

CILOXAN® (ciprofloxacin hydrochloride)

See more

CO-DIOVAN® (valsartan/hydrochlorothiazide)

See more

COSENTYX® (secukinumab)

See more

DESFERAL® (deferoxamine mesilate)

See more

DIOVAN® (valsartan)

See more

DUOTRAV® (timolol maleate/travoprost)

See more

ENERZAIR® BREEZHALER® (indacaterol/glycopyrronium/mometasone furoate)

See more

ENTRESTO® (sacubitril/valsartan)

See more

ERELZI® (etanercept)

See more

ESTRADOT® (estradiol hemihydrate)

See more

EUCREAS® (vildagliptin/metformin)

See more

EXELON® (rivastigmine hydrogen tartrate)

See more

EXELON® PATCH (rivastigmine)

See more

EXJADE® (deferasirox)

See more

FEMARA® (letrozole)

See more

FORADIL® (formoterol)

See more

GALVUS® (vildagliptin)

See more

GILENYA® (fingolimod)

See more

GLIVEC® (imatinib)

See more

HYCAMTIN® (topotecan hydrochloride)

See more

HYRIMOZ® (adalimumab)

See more

ILARIS® (canakinumab)

See more

JAKAVI® (ruxolitinib)

See more

KESIMPTA® (ofatumumab)

See more

KISQALI® (ribociclib)

See more

KYMRIAH® (tisagenlecleucel)

See more

LAMISIL® (terbinafine)

See more

LEQVIO® (inclisiran)

See more

LESCOL® XL (fluvastatin)

See more

LIORESAL® (baclofen)

See more

LUCENTIS® (ranibizumab)

See more

LYSAKARE® (l-arginine/l-lysine)

See more

MAXIDEX® (dexamethasone)

See more

MAXITROL® (dexamethasone/polymyxin b sulfate/neomycin sulfate)

See more

MAYZENT® (siponimod)

See more

MEKINIST® (trametinib)

See more

MYFORTIC® (mycophenolic acid)

See more

NEORAL® (ciclosporin)

See more

NEVANAC® (nepafenac)

See more

ONBREZ® BREEZHALER® (indacaterol)

See more

OPATANOL® (olopatadine (as hydrochloride))

See more

REVOLADE® (eltrombopag)

See more

RYDAPT® (midostaurin)

See more

SANDIMMUN® (ciclosporin)

See more

SANDOSTATIN®/SANDOSTATIN LAR® (octreotide)

See more

SEEBRI® BREEZHALER® (glycopyrronium)

See more

SIMBRINZA® (brinzolamide/brimonidine tartrate)

See more

SIMULECT® (basiliximab)

See more

SOMAKIT® (edotreotide)

See more

TAFINLAR® (dabrafenib)

See more

TASIGNA® (nilotinib)

See more

TEGRETOL® (carbamazepine)

See more

TRANSIDERM NITRO® (glyceril trinitrate)

See more

TRAVATAN® (travoprost)

See more

TRILEPTAL® (oxcarbazapine)

See more

TYVERB® (lapatinib)

See more

ULTIBRO® BREEZHALER® (indacaterol/glycopyrronium)

See more

VOLTAROL® (diclofenac sodium)

See more

VOTRIENT® (pazopanib)

See more

XOLAIR® (omalizumab)

See more

ZOFRAN® (ondansetron)

See more

ZOLGENSMA® (onasemnogene abeparvovec)

See more

ZYKADIA® (ceritinib)

See more
Rate this content: 
No votes yet
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.